Morning Overview on MSN
A year of added prostate-cancer therapy cut the odds the disease spreads, a major trial found
Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...
Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...
The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Prostate cancer remains a significant public health concern, with a substantial proportion of patients experiencing biochemical recurrence (BCR) after radical prostatectomy (RP). Traditional risk ...
High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...
Salvage radiotherapy (SRT) is the standard of care for patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Several randomized trials have evaluated the addition of hormonal ...
After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of recurrence after the five-year mark ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
Gabby Logan's husband, Kenny Logan, continues to have check-ups every six months after receiving the all-clear from prostate ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results